OptimizeRx (OPRX) Q4 2025 earnings summary

Executive summary

• Q4 and FY 2025 results exceeded expectations, with strong revenue and adjusted EBITDA growth driven by both established and new clients, especially in mid-tier and long-tail life science companies.

• Q4 2025 revenue was $32.2M, nearly flat year-over-year, while full-year revenue grew 19% to $109.4M compared to 2024.

• Q4 gross profit rose 9% year-over-year to $24.1M; full-year gross profit reached $73.6M, up from $59.4M.

• Q4 GAAP net income was $5M versus a net loss in Q4 2024; full-year GAAP net income was $5.1M, reversing a $20.1M loss in 2024.

• Product mix improvements, channel partner strategy, and cost optimization post-Medicx acquisition led to higher gross margins and more than doubled adjusted EBITDA and free cash flow year-over-year.

Financial highlights

• Q4 2025 revenue: $32.2M; adjusted EBITDA: $12M; net income: $5M ($0.26 per diluted share); Non-GAAP net income: $9.9M ($0.51 per diluted share).

• FY 2025 revenue: $109.4M; adjusted EBITDA: $24.3M; operating cash flow: $18.7M (vs. $4.9M in 2024); cash and short-term investments: $23.4M (vs. $13.4M in 2024).

• Full-year non-GAAP net income was $19.9M ($1.05/share), up from $6.2M ($0.33/share) in 2024.

• Gross margin for Q4 2025: 74.8% (vs. 68.1% in Q4 2024), attributed to favorable solution and channel partner mix; not expected to be sustained in 2026.

• Debt balance at year-end: $26.3M, with $8M principal paid off in 2025, including $6M ahead of schedule.

Outlook and guidance

• 2026 revenue guidance: $109M–$114M; adjusted EBITDA: $21M–$25M, reflecting a more conservative revenue outlook but continued focus on profitability.

• Revenue phasing expected to return to historical 40%-60% split between first and second half, with a stronger back half anticipated.

• Minimal managed services revenue expected in 2026; guidance assumes little contribution from this segment.

• Management remains focused on sustaining Rule of 40 performance and expects continued strength into 2026.